Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 11 of the 105 sources its claims cite were checked for support.

Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review

Open access
Oscarsson, Jan, Hurt-Camejo, Eva · 2017 · Lipids in Health and Disease

Abstract

BACKGROUND: Epidemiological and genetic studies suggest that elevated triglyceride (TG)-rich lipoprotein levels in the circulation increase the risk of cardiovascular disease. Prescription formulations of omega-3 fatty acids (OM3FAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), reduce plasma TG levels and are approved for the treatment of patients with severe hypertriglyceridemia. Many preclinical studies have investigated the TG-lowering mechanisms of action of OM3FAs, but less is known from clinical studies. METHODS: We conducted a review, using systematic methodology, of studies in humans assessing the mechanisms of action of EPA and DHA on apolipoprotein B-containing lipoproteins, including TG-rich lipoproteins and low-density lipoproteins (LDLs). A systematic search of PubMed retrieved 55 articles, of which 30 were used in the review; 35 additional arrticles were also included. RESULTS: In humans, dietary DHA is retroconverted to EPA, while production of DHA from EPA is not observed. Dietary DHA is preferentially esterified into TGs, while EPA is more evenly esterified into TGs, cholesterol esters and phospholipids. The preferential esterification of DHA into TGs likely explains the higher turnover of DHA than EPA in plasma. The main effects of both EPA and DHA are decreased fasting and postprandial serum TG levels, through reduction of hepatic very-low-density lipoprotein (VLDL)-TG production. The exact mechanism for reduced VLDL production is not clear but does not include retention of lipids in the liver; rather, increased hepatic fatty acid oxidation is likely. The postprandial reduction in TG levels is caused by increased lipoprotein lipase activity and reduced serum VLDL-TG concentrations, resulting in enhanced chylomicron clearance. Overall, no clear differences between the effects of EPA and DHA on TG levels, or on turnover of TG-rich lipoproteins, have been observed. Effects on LDL are complex and may be influenced by genetics, such as APOE genotype. CONCLUSIONS: EPA and DHA diminish fasting circulating TG levels via reduced production of VLDL. The mechanism of reduced VLDL production does not involve hepatic retention of lipids. Lowered postprandial TG levels are also explained by increased chylomicron clearance. Little is known about the specific cellular and biochemical mechanisms underlying the TG-lowering effects of EPA and DHA in humans.

Overview

CoChat Summary

TL;DR

This review summarizes human studies on how EPA and DHA lower apolipoprotein B-containing lipoproteins, concluding that both reduce fasting and postprandial triglycerides mainly by decreasing hepatic VLDL production and increasing postprandial LPL-mediated chylomicron clearance. It finds no clear overall difference between EPA and DHA for triglyceride lowering, while LDL effects are complex and may be influenced by APOE genotype.

Key findings

  • In humans, dietary DHA is retroconverted to EPA, but EPA is not converted to DHA; DHA is preferentially esterified into TGs, whereas EPA is more evenly esterified into TGs, cholesterol esters, and phospholipids.
  • Both EPA and DHA lower fasting and postprandial TG levels similarly; prescription-grade OM3FAs at about 2–4 g/day reduce plasma TG by about 30%, and the review reports no clear difference between EPA and DHA for TG lowering.
  • The major mechanism is reduced hepatic VLDL production: Chan et al. found OM3FAs decreased hepatic VLDL-apoB production by 29% more than corn oil and hepatic TG synthesis by 35%; Ouguerram et al. found VLDL1 production decreased with unchanged fractional catabolic rate.
  • Postprandial TG reduction is explained by increased LPL activity and enhanced chylomicron clearance; DHA and EPA increased pre-heparin LPL activity and reduced chylomicron TG half-lives. LDL effects are small or inconsistent and may depend on APOE genotype, with DHA increasing LDL-C in APOE4 carriers in some studies.

Methods

  • Systematic review of human studies; PubMed was searched on December 8, 2015 and updated May 1, 2016 using combined DHA/EPA, outcomes, and mechanism-of-action terms; reviews were excluded and filters limited to human studies and English-language publications.
  • The search identified 953 articles for screening, 55 potentially relevant articles, and 30 used in the review; 35 additional articles were included for context and completeness.
  • Narrative synthesis of clinical studies on production and clearance of apoB-containing lipoproteins (VLDL, chylomicrons, LDL), including kinetic, postprandial, LPL, apolipoprotein, and LDL composition/size studies.

Limitations

  • Stated: little is known about the specific cellular and biochemical mechanisms underlying TG-lowering by EPA and DHA in humans; the exact mechanism for reduced VLDL production is not clear; detailed studies on post-translational LPL regulation are generally lacking; and few studies compare EPA versus DHA effects on apoCII and apoCIII.
  • Evident: the review is not a meta-analysis, and 35 included articles were not identified by the systematic search; included studies vary in design, dose, duration, and population, with some kinetic studies having very small samples (e.g., n = 4, n = 5, n = 7).
  • Evident: some mechanistic evidence comes from in vitro hepatocyte studies or surrogate markers (e.g., blood cell LDL receptor mRNA), limiting direct human mechanistic conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12944-017-0541-3

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flow diagram of article screening and evaluation
Fig. 1 Flow diagram of article screening and evaluationCC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 51 Not checked · 29 Own results and interpretations

58 more claims · 3 with their cited sources checked

Create a free account to see all 89 claims and to verify the 94 references still open.

See all claims — free account
  • It may state two separate claims as one. 26

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 65 references

Cited by

See all 158

Metadata

Authors
Oscarsson, J., & Hurt-Camejo, E.
Affiliations
AstraZeneca (Sweden) (SE)
Corresponding author
Oscarsson, Jan
Venue
Lipids in Health and Disease
Published
2017-08-10
Volume
16
Issue
1
Pages
149-149
ISSN
1476-511X (ISSN-L)
OpenAlex
W2744078963
Cited by
158
References
65
Citations by year
2026: 12 · 2025: 18 · 2024: 23 · 2023: 22 · 2022: 18 · 2021: 14 · 2020: 28 · 2019: 11 · 2018: 9 · 2017: 1
FWCI
1.38
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Lipids in Health and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
AstraZeneca
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, apolipoprotein B-containing lipoproteins, triglyceride-rich lipoproteins, low-density lipoprotein, hypertriglyceridemia, VLDL, hepatic fatty acid oxidation, lipoprotein lipase, chylomicron clearance, postprandial triglycerides, APOE genotype, cardiovascular disease
MeSH terms
Apolipoproteins B, Apolipoproteins E, Biotransformation, Chylomicrons, Docosahexaenoic Acids, Fasting, Humans, Lipoprotein Lipase, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Liver, Oxidation-Reduction, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Postprandial Period, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. https://app.cochat.ai/papers/10.1186/s12944-017-0541-3
The paper
Oscarsson, J., & Hurt-Camejo, E. (2017). Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids in Health and Disease. https://doi.org/10.1186/s12944-017-0541-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.